Oligofructose | whatsinit

About

What it is and where it shows up.

Oligofructose is a naturally occurring prebiotic dietary fiber composed of short-chain fructose polymers (degree of polymerization 2–8), found naturally in chicory root, onions, garlic, and wheat, and commercially produced by partial hydrolysis of inulin or enzymatic synthesis from sucrose. It is widely used in food and beverage products to enhance dietary fiber content, promote beneficial gut microbiota, and serve as a low-calorie bulking agent.

Safety summary

The regulatory and scientific consensus.

Oligofructose is broadly considered safe at typical dietary intake levels with no established ADI; however, doses exceeding approximately 10–20 g/day may cause gastrointestinal side effects such as bloating, flatulence, abdominal cramping, and diarrhea due to rapid colonic fermentation. Individuals with irritable bowel syndrome (IBS) are particularly sensitive due to its classification as a fermentable FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols) carbohydrate. Regulatory authorities in the US (FDA GRAS), EU (permitted dietary fiber ingredient), and India (FSSAI-approved nutritional ingredient) have affirmed its safety for general food use.

Regulatory landscape

What food-safety regulators have decided.

Jurisdiction	Status	Note
EFSA (European Food Safety Authority) (European Union)	Approved	Not classified as a food additive and therefore not assigned an E number in the EU; freely permitted as a food ingredient (dietary fibre) under Regulation (EC) No 1333/2008 framework; EFSA has evaluated inulin-type fructans including oligofructose in the context of infant formula and health claims under Regulation (EC) No 1924/2006source
FSSAI (Food Safety and Standards Authority of India) (India)	Approved	Approved as a nutritional ingredient under Food Safety and Standards (Food Product Standards and Food Additives) Regulation, 2011, via Gazette Notification dated 23 March 2015; subject to labelling requirements as a nutritional ingredientsource
FDA (Food and Drug Administration) (United States)	Approved	Supplementary GRAS Notice GRN 605 covering fructooligosaccharides (FOS) more broadly; supports safety consensus for all short-chain FOS ingredients in food usesource

Who should approach with care

Whose guidance would steer them away.

Ibs — Oligofructose is a fermentable FODMAP carbohydrate; its rapid colonic fermentation produces gas and osmotic fluid shifts that commonly trigger or worsen bloating, cramping, and diarrhea in IBS patients, and it is specifically restricted on low-FODMAP dietary protocols.

Ibd — High doses of rapidly fermentable fibers such as oligofructose may exacerbate gastrointestinal inflammation and symptoms in individuals with active Crohn's disease or ulcerative colitis.

Infants — Appropriate oligofructose levels in infant formula are subject to specific regulatory scrutiny (including EFSA and FSSAI infant food provisions); caregivers should consult a pediatrician before introducing high-FOS products to infants under 12 months.

Other — Individuals undergoing abdominal surgery recovery or with small intestinal bacterial overgrowth (SIBO) should limit or avoid oligofructose due to excessive fermentation and gas production in the gut.

Research citations

The sources behind this verdict.

1FDA. GRAS Notice No. 392: Oligofructose. cfsanappsexternal.fda.gov
2FDA. GRAS Notice No. 605: Fructo-oligosaccharides. fda.gov
3PubMed. Dietary fructooligosaccharides and inulin decrease resistance of rats to Salmonella: protective role of cecal microflora and FODMAP-related gastrointestinal effects. pubmed.ncbi.nlm.nih.gov
4FSSAI. Gazette Notification on Food Safety and Standards (Food Product Standards and Food Additives) Regulation, 2011 – Use of Nutritional Ingredients including Oligofructose, 2015. archive.fssai.gov.in
5EFSA. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA): Scientific Opinion on the substantiation of health claims related to fructooligosaccharides and oligofructose, 2011. efsa.europa.eu

Independently researched5 citations